News about "Eli Lilly"

Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

Rznomics joins Lilly Gateway Labs in San Diego to accelerate RNA therapeutics development, expand global partnerships and advance its pipeline of 200+ disease targets.

Eli Lilly | 25/08/2026 | By News Bureau

AlzeCure Receives USD 10 Million Upfront Payment from Eli Lilly for Alzheimer's Drug Programme

AlzeCure Pharma has received a USD 10 million upfront payment from Eli Lilly, completing the initial transaction for global rights to its Alzstatin Alzheimer's programme and ACD680.

Eli Lilly | 20/08/2026 | By News Bureau

Amplitude Therapeutics and Lilly Partner on RNA Vaccines for Infectious Diseases

Amplitude Therapeutics and Lilly partner to develop trans-amplifying RNA vaccines for infectious diseases, combining taRNA technology with Lilly’s global capabilities.

Eli Lilly | 20/08/2026 | By News Bureau |  249

OmniAb and Eli Lilly Partner on Ion Channel Program

OmniAb and Eli Lilly enter a global collaboration for an ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel discovery and screening.

Eli Lilly | 17/08/2026 | By News Bureau |  108

Lilly Urges Action against Illegal Retatrutide Black Market

Eli Lilly has filed 6 new lawsuits against US entities selling illegal retatrutide products, escalating efforts to protect patients from the black market.

Eli Lilly | 12/08/2026 | By News Bureau

Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials

Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials. The company plans to submit a Biologics License Application (BLA) for retatrutide to the US Food and Drug Administration (FDA) in Q1 2027.

Eli Lilly | 25/07/2026 | By News Bureau |  116

Innovent and Lilly Partner to Commercialise Verzenios in China

Innovent Biologics and Eli Lilly have signed a commercialisation agreement for Verzenios (abemaciclib) in mainland China, expanding access to the CDK4/6 inhibitor for cancer patients.

Eli Lilly | 01/07/2026 | By News Bureau

CHMP Recommends Lilly's Jaypirca for CLL Treatment in EU

CHMP has recommended Lilly’s Jaypirca (pirtobrutinib) for EU approval in adults with chronic lymphocytic leukemia (CLL), potentially expanding its use across all lines of therapy.

Eli Lilly | 29/06/2026 | By News Bureau

Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies

Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.

Eli Lilly | 26/06/2026 | By News Bureau |  118

Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL

Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.

Eli Lilly | 15/06/2026 | By News Bureau